marketcaparena
Search

    TWST

    Twist Bioscience Corp

    Company overview

    Market capitalization
    $11.26B
    Employees
    979
    Latest publication
    2026-09-29
    About Twist Bioscience Corp

    Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ3 20262026-06-30 · USDQ2 20172017-03-31 · USDQ1 20172016-12-31 · USDQ4 20162016-09-30 · USD
    Total Revenue118,376,000USD2,433,000USD1,692,000USD2,269,000USD
    Cost Of Revenue55,922,000USD5,984,000USD4,987,000USD7,592,000USD
    Gross Profit62,454,000USD0USD0USD-7,152,000USD
    Research Development18,025,000USD4,709,000USD4,332,000USD15,830,000USD
    Selling General Administrative80,709,000USD10,701,000USD10,072,000USD34,104,000USD
    Total Operating Expenses98,734,000USD0USD0USD45,925,000USD
    Operating Income-36,280,000USD0USD0USD-43,656,000USD
    Total Other Income Expense Net1,540,000USD0USD0USD-432,000USD
    Interest Income1,500,000USD———
    Litigation Settlement Expense0USD———
    Income Before Tax-34,740,000USD0USD0USD-44,088,000USD
    Income Tax Expense311,000USD58,000USD33,000USD0USD
    Net Income-35,051,000USD0USD0USD-44,088,000USD
    Unclassified Operating Expenses—-15,410,000USD-14,404,000USD-4,009,000USD
    Interest Expense—199,000USD192,000USD746,000USD
    Net Income From Continuing Ops—0USD0USD-44,088,000USD
    Ebit—0USD0USD-43,656,000USD
    Minority Interest—0USD0USD0USD
    Discontinued Operations—0USD0USD0USD
    Net Income Applicable To Common Shares—0USD0USD-44,088,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ3 20262026-06-30 · USDQ2 20262026-03-31 · USDQ1 20262025-12-31 · USDQ4 20252025-09-30 · USDQ3 20252025-06-30 · USDQ2 20252025-03-31 · USDQ1 20252024-12-31 · USDQ4 20242024-09-30 · USD
    Total Assets672,437,000USD676,214,000USD638,085,000USD641,861,000USD643,605,000USD595,615,000USD608,580,000USD614,323,000USD
    Cash And Equivalents117,436,000USD———————
    Cash And Short Term Investments166,839,000USD171,671,000USD197,949,000USD232,434,000USD250,798,000USD257,147,000USD270,827,000USD276,399,000USD
    Short Term Investments49,403,000USD49,001,000USD49,358,000USD49,385,000USD49,425,000USD46,710,000USD49,424,000USD50,083,000USD
    Total Current Assets321,295,000USD323,439,000USD303,882,000USD332,966,000USD339,776,000USD338,442,000USD345,309,000USD346,776,000USD
    Other Current Assets1,752,000USD54,100,000USD22,947,000USD14,904,000USD13,186,000USD10,486,000USD11,649,000USD11,396,000USD
    Other Non Current Assets5,376,000USD———————
    Total Liabilities226,698,000USD———————
    Total Current Liabilities120,255,000USD119,976,000USD80,441,000USD91,406,000USD87,070,000USD74,976,000USD69,646,000USD71,006,000USD
    Other Current Liabilities59,703,000USD———————
    Other Non Current Liabilities6,483,000USD———————
    Total Stockholder Equity445,739,000USD455,094,000USD456,095,000USD472,958,000USD478,198,000USD440,108,000USD455,941,000USD472,689,000USD
    Total Equity Including Noncontrolling Interest445,739,000USD———————
    Deferred Revenue6,466,000USD———————
    Deferred Revenue Non Current5,668,000USD———————
    Net Receivables65,055,000USD64,153,000USD50,062,000USD57,319,000USD49,854,000USD49,949,000USD39,315,000USD34,903,000USD
    Inventory35,162,000USD33,515,000USD32,924,000USD28,309,000USD25,938,000USD20,860,000USD23,518,000USD24,078,000USD
    Property Plant Equipment Net180,624,000USD181,881,000USD177,385,000USD151,660,000USD147,196,000USD151,208,000USD157,144,000USD161,349,000USD
    Goodwill82,195,000USD———————
    Accounts Payable17,043,000USD14,682,000USD12,493,000USD11,094,000USD11,985,000USD8,063,000USD7,503,000USD1,630,000USD
    Short Term Debt8,630,000USD10,443,000USD12,242,000USD13,822,000USD15,501,000USD15,218,000USD15,030,000USD14,805,000USD
    Common Stock1,000USD1,000USD——————
    Retained Earnings-1,429,157,000USD-1,394,106,000USD-1,350,085,000USD-1,319,578,000USD-1,292,440,000USD-1,312,830,000USD-1,273,502,000USD-1,241,908,000USD
    Accumulated Other Comprehensive Income-655,000USD-639,000USD-571,000USD-627,000USD-864,000USD—-649,000USD-522,000USD
    Intangible Assets—12,996,000USD13,162,000USD13,425,000USD13,688,000USD13,951,000USD14,215,000USD14,478,000USD
    Total Liab—221,120,000USD181,990,000USD168,903,000USD165,407,000USD155,507,000USD152,639,000USD141,634,000USD
    Other Current Liab—87,756,000USD46,689,000USD59,606,000USD49,007,000USD51,695,000USD43,846,000USD34,910,000USD
    Capital Stock—1,000USD0USD0USD0USD0USD0USD0USD
    Good Will—82,195,000USD82,195,000USD82,195,000USD82,195,000USD85,811,000USD85,811,000USD85,811,000USD
    Cash—122,670,000USD148,591,000USD183,049,000USD201,373,000USD210,437,000USD221,403,000USD226,316,000USD
    Current Deferred Revenue—7,095,000USD9,017,000USD6,884,000USD6,324,000USD——2,131,000USD
    Net Debt—-26,829,000USD35,267,000USD-45,727,000USD-123,223,000USD-130,139,000USD-138,787,000USD-141,290,000USD
    Short Long Term Debt Total—95,841,000USD183,858,000USD137,322,000USD78,150,000USD80,298,000USD82,616,000USD85,026,000USD
    Long Term Investments—68,087,000USD54,337,000USD54,337,000USD54,337,000USD———
    Property Plant Equipment Gross—287,792,000USD277,551,000USD246,654,000USD236,478,000USD238,702,000USD238,532,000USD236,992,000USD
    Common Stock Shares Outstanding—61,702,000shares61,080,000shares60,424,000shares61,164,000shares59,649,000shares59,162,000shares58,016,000shares
    Non Current Assets Total—352,775,000USD334,203,000USD308,895,000USD303,829,000USD257,173,000USD263,271,000USD267,547,000USD
    Non Current Liabilities Total—101,144,000USD101,549,000USD77,496,999USD78,337,000USD80,531,000USD82,993,000USD70,628,000USD
    Non Current Liabilities Other—746,000USD741,000USD747,000USD15,688,000USD15,451,000USD15,407,000USD407,000USD
    Non Currrent Assets Other—7,616,000USD7,124,000USD3,102,000USD6,413,000USD105,965,000USD6,101,000USD5,909,000USD
    Net Working Capital—203,463,000USD223,441,000USD241,560,000USD252,706,000USD263,466,000USD275,663,000USD275,770,000USD
    Unclassified Non Current Liabilities—100,398,000USD100,808,000USD76,749,999USD62,649,000USD65,080,000USD67,586,000USD70,221,000USD
    Unclassified Equity—1,849,837,000USD1,806,751,000USD1,793,163,000USD1,771,502,000USD1,752,938,000USD1,730,092,000USD1,715,119,000USD
    Unclassified Non Current Assets———4,176,000USD—-99,762,000USD——
    Unclassified Current Liabilities————4,253,000USD—3,267,000USD17,530,000USD
    Long Term Debt—————0USD0USD0USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-09-30 · USDFY 20242024-09-30 · USDFY 20232023-09-30 · USDFY 20222022-09-30 · USDFY 20212021-09-30 · USDFY 20202020-09-30 · USDFY 20192019-09-30 · USDFY 20182018-09-30 · USD
    Total Assets641,861,000USD614,323,000USD776,403,000USD961,378,000USD702,097,000USD398,882,000USD186,994,000USD115,791,000USD
    Intangible Assets13,425,000USD14,478,000USD54,483,000USD59,738,000USD18,262,000USD307,000USD508,000USD712,000USD
    Other Current Assets14,904,000USD11,396,000USD11,716,000USD11,914,000USD8,283,000USD7,154,000USD2,594,000USD3,467,000USD
    Total Liab168,903,000USD141,634,000USD152,971,000USD171,993,000USD121,276,000USD62,620,000USD34,912,000USD317,213,000USD
    Total Stockholder Equity472,958,000USD472,689,000USD623,432,000USD789,385,000USD580,821,000USD336,262,000USD152,082,000USD-201,422,000USD
    Other Current Liab59,606,000USD49,715,000USD37,002,000USD53,453,000USD34,859,000USD21,457,000USD17,261,000USD939,000USD
    Capital Stock0USD0USD0USD0USD0USD0USD0USD0USD
    Retained Earnings-1,319,578,000USD-1,241,908,000USD-1,033,034,000USD-828,416,000USD-610,553,000USD-458,455,000USD-318,524,000USD-210,855,000USD
    Good Will82,195,000USD85,811,000USD85,811,000USD85,811,000USD22,434,000USD1,138,000USD1,138,000USD1,138,000USD
    Cash183,049,000USD226,316,000USD286,470,000USD378,687,000USD465,829,000USD93,667,000USD46,735,000USD80,757,000USD
    Cash And Short Term Investments232,434,000USD276,399,000USD336,413,000USD504,968,000USD477,863,000USD290,002,000USD138,107,000USD80,757,000USD
    Total Current Assets332,966,000USD346,776,000USD424,256,000USD596,483,000USD546,495,000USD334,870,000USD160,135,000USD95,671,000USD
    Total Current Liabilities91,406,000USD71,006,000USD73,323,000USD90,663,000USD63,052,000USD36,029,000USD30,354,000USD18,537,000USD
    Current Deferred Revenue6,884,000USD2,131,000USD2,999,000USD3,476,000USD1,088,000USD18,846,000USD16,444,000USD7,567,000USD
    Net Debt-45,727,000USD-141,290,000USD-192,401,000USD-283,775,000USD-402,908,000USD-57,685,000USD-39,002,000USD-71,039,000USD
    Short Term Debt13,822,000USD14,805,000USD14,896,000USD13,642,000USD9,765,000USD9,742,000USD3,333,000USD2,500,000USD
    Short Long Term Debt Total137,322,000USD85,026,000USD94,069,000USD94,912,000USD62,921,000USD35,982,000USD7,733,000USD300,832,000USD
    Long Term Investments54,337,000USD1,525,000USD——————
    Short Term Investments49,385,000USD50,083,000USD49,943,000USD126,281,000USD12,034,000USD196,335,000USD91,372,000USD0USD
    Net Receivables57,319,000USD34,903,000USD44,064,000USD40,294,000USD28,549,000USD25,425,000USD12,104,000USD5,419,000USD
    Inventory28,309,000USD24,078,000USD32,063,000USD39,307,000USD31,800,000USD12,289,000USD7,330,000USD6,028,000USD
    Accounts Payable11,094,000USD1,630,000USD14,052,000USD20,092,000USD14,900,000USD4,830,000USD9,760,000USD7,531,000USD
    Property Plant Equipment Net151,660,000USD161,349,000USD203,361,000USD214,389,000USD105,702,000USD59,165,000USD20,835,000USD12,331,000USD
    Property Plant Equipment Gross246,654,000USD236,992,000USD203,361,000USD214,389,000USD105,702,000USD59,165,000USD20,835,000USD12,331,000USD
    Accumulated Other Comprehensive Income-627,000USD-522,000USD-756,000USD-1,843,000USD546,000USD86,999USD181,000USD87,000USD
    Common Stock Shares Outstanding59,808,000shares58,016,000shares56,885,000shares53,885,000shares48,251,000shares39,190,000shares27,462,000shares26,609,991shares
    Non Current Assets Total308,895,000USD267,547,000USD352,147,000USD364,895,000USD155,602,000USD64,012,000USD26,859,000USD20,120,000USD
    Non Current Liabilities Total77,497,000USD70,628,000USD79,648,000USD81,330,000USD58,224,000USD26,591,000USD4,558,000USD298,676,000USD
    Non Current Liabilities Other747,000USD407,000USD475,000USD60,000USD58,224,000USD25,188,000USD158,000USD344,000USD
    Non Currrent Assets Other7,278,000USD4,384,000USD5,681,000USD4,957,000USD9,204,000USD3,402,000USD4,378,000USD5,939,000USD
    Net Working Capital241,560,000USD275,770,000USD350,933,000USD505,820,000USD483,443,000USD298,841,000USD129,781,000USD77,134,000USD
    Unclassified Non Current Liabilities76,750,000USD70,221,000USD79,173,000USD81,210,000USD-5,068,000USD——287,070,000USD
    Unclassified Equity1,793,163,000USD1,715,119,000USD1,657,222,000USD830,259,000USD610,007,000USD458,368,001USD657,419,000USD9,977,000USD
    Unclassified Current Liabilities—2,725,000USD4,374,000USD——-22,179,000USD-19,777,000USD-2,500,000USD
    Other Assets——-1,000USD-1,000USD49,900,000USD3,402,000USD4,378,000USD5,939,000USD
    Common Stock———789,385,000USD580,821,000USD336,262,000USD-186,994,000USD-631,000USD
    Other Liab———60,000USD5,068,000USD351,000USD158,000USD344,000USD
    Net Tangible Assets———789,385,000USD540,125,000USD334,817,000USD150,436,000USD-203,272,000USD
    Short Long Term Debt————1,552,000USD3,333,000USD3,333,000USD2,500,000USD
    Unclassified Non Current Assets————-49,900,000USD-3,402,000USD-4,378,000USD-5,939,000USD
    Long Term Debt—————1,403,000USD4,400,000USD7,218,000USD
    Deferred Long Term Liab———————3,700,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ3 20262026-06-30 · USD
    Depreciation19,386,000USD
    Stock Based Compensation50,385,000USD
    Other Non Cash Items673,000USD
    Change To Account Receivables-8,497,000USD
    Change To Inventory-6,852,000USD
    Change To Liabilities30,233,000USD
    Change In Working Capital-26,430,000USD
    Operating Cash Flow-41,258,000USD
    Capital Expenditures-27,624,000USD
    Net Investments-112,000USD
    Unclassified Investing Cash Flow-5,101,000USD
    Investing Cash Flow-32,837,000USD
    Common Stock Issuance5,882,000USD
    Unclassified Financing Cash Flow2,341,000USD
    Financing Cash Flow8,223,000USD
    Effect Of Forex Changes On Cash13,000USD
    Change In Cash-65,859,000USD
    End Cash Flow119,566,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-03-31 · USDQ1 20262025-12-31 · USDQ4 20252025-09-30 · USDQ3 20252025-06-30 · USDQ2 20252025-03-31 · USDQ1 20252024-12-31 · USDQ4 20242024-09-30 · USDQ3 20242024-06-30 · USD
    Net Income-44,021,000USD-30,507,000USD-27,138,000USD20,390,000USD-39,328,000USD-31,594,000USD-34,655,000USD-85,571,000USD
    Depreciation6,414,000USD6,194,000USD6,004,000USD6,065,000USD6,404,000USD6,380,000USD6,656,000USD8,301,000USD
    Stock Based Compensation18,936,000USD13,273,000USD16,083,000USD16,057,000USD20,328,000USD11,991,000USD12,347,000USD13,734,000USD
    Other Non Cash Items-498,000USD-336,000USD220,000USD-47,695,000USD831,000USD-20,000USD1,472,000USD44,596,000USD
    Change To Account Receivables-14,238,000USD6,826,000USD-7,210,000USD87,000USD-10,722,000USD-4,537,000USD-2,954,000USD3,997,000USD
    Change To Inventory-590,000USD-4,615,000USD-2,368,000USD-5,078,000USD2,657,000USD560,000USD4,408,000USD1,891,000USD
    Change In Working Capital1,610,000USD-13,438,000USD-6,983,000USD3,783,000USD-1,221,000USD-8,185,000USD-1,140,000USD12,562,000USD
    Total Cash From Operating Activities-17,559,000USD-24,814,000USD-11,814,000USD-1,400,000USD-12,986,000USD-21,428,000USD-15,320,000USD-6,378,000USD
    Capital Expenditures-7,987,000USD-9,974,000USD-12,427,000USD-9,165,000USD-4,144,000USD-2,268,000USD-2,002,000USD-965,000USD
    Free Cash Flow-25,546,000USD-34,788,000USD-24,241,000USD-10,565,000USD-17,130,000USD-23,696,000USD-17,322,000USD-7,343,000USD
    Investments281,000USD41,000USD-12,403,000USD-9,397,000USD-1,426,000USD-1,536,000USD-1,285,000USD-711,000USD
    Total Cashflows From Investing Activities-12,706,000USD-9,933,000USD-12,403,000USD-9,397,000USD-1,426,000USD-1,536,000USD-1,285,000USD-711,000USD
    Total Cash From Financing Activities4,138,000USD298,000USD5,574,000USD1,826,000USD3,196,000USD17,944,000USD3,627,000USD2,908,000USD
    Sale Purchase Of Stock-8,000USD-2,000USD-2,000USD-3,000USD-5,000USD-6,000USD-8,000USD-7,000USD
    Change In Cash-26,133,000USD-34,440,000USD-18,480,000USD-9,042,000USD-11,112,000USD-5,073,000USD-12,905,000USD-4,179,000USD
    Begin Period Cash Flow150,985,000USD185,425,000USD203,905,000USD212,947,000USD224,059,000USD229,132,000USD242,037,000USD246,216,000USD
    End Period Cash Flow124,852,000USD150,985,000USD185,425,000USD203,905,000USD212,947,000USD224,059,000USD229,132,000USD242,037,000USD
    Other Cashflows From Investing Activities-5,100,000USD——2,500,000USD——-1USD—
    Other Cashflows From Financing Activities4,138,000USD298,000USD5,576,000USD1,826,000USD3,201,000USD17,950,000USD3,635,000USD2,915,000USD
    Unclassified Investing Cash Flow——12,427,000USD6,665,000USD4,144,000USD2,268,000USD2,002,001USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-09-30 · USDFY 20242024-09-30 · USDFY 20232023-09-30 · USDFY 20222022-09-30 · USDFY 20212021-09-30 · USDFY 20202020-09-30 · USDFY 20192019-09-30 · USDFY 20182018-09-30 · USD
    Net Income-77,670,000USD-208,726,000USD-204,618,000USD-217,863,000USD-152,098,000USD-139,931,000USD-107,669,000USD-71,236,000USD
    Depreciation24,853,000USD31,432,000USD29,310,000USD16,514,000USD9,750,000USD6,677,000USD6,111,000USD5,727,000USD
    Stock Based Compensation64,459,000USD50,925,000USD30,278,000USD79,664,000USD36,998,000USD17,096,000USD11,170,000USD2,961,000USD
    Other Non Cash Items-46,664,000USD46,864,000USD3,975,000USD2,656,000USD2,487,000USD-707,000USD515,000USD562,000USD
    Change To Account Receivables-22,382,000USD8,444,000USD-4,320,000USD-9,622,000USD-2,202,000USD-14,272,000USD-6,685,000USD-3,073,000USD
    Change To Inventory-4,229,000USD7,986,000USD7,238,000USD-7,536,000USD-19,489,000USD-4,956,000USD-1,302,000USD-4,202,000USD
    Change In Working Capital-12,606,000USD15,411,000USD-1,009,000USD-5,356,000USD-9,381,000USD-25,176,000USD2,996,000USD-4,220,000USD
    Total Cash From Operating Activities-47,628,000USD-64,094,000USD-142,474,000USD-124,385,000USD-112,244,000USD-142,255,000USD-87,937,000USD-66,164,000USD
    Capital Expenditures-28,004,000USD-5,076,000USD-27,779,000USD-101,857,000USD-27,061,000USD-9,868,000USD-14,757,000USD-3,688,000USD
    Free Cash Flow-75,632,000USD-69,170,000USD-170,253,000USD-226,242,000USD-139,305,000USD-152,123,000USD-102,694,000USD-69,852,000USD
    Investments-24,762,000USD-3,071,000USD50,612,000USD-117,158,000USD183,699,000USD-104,782,000USD-90,074,000USD30,977,000USD
    Total Cashflows From Investing Activities-24,762,000USD-3,071,000USD50,612,000USD-232,930,000USD156,155,000USD-114,650,000USD-104,810,000USD26,872,000USD
    Total Cash From Financing Activities28,540,000USD6,890,000USD911,000USD270,534,000USD329,182,000USD303,732,000USD158,578,000USD88,822,000USD
    Sale Purchase Of Stock-16,000USD-3,975,000USD-4,405,000USD-7,754,000USD-10,849,000USD-2,421,000USD161,078,000USD91,181,000USD
    Change In Cash-43,267,000USD-60,149,000USD-90,978,000USD-87,100,000USD373,113,000USD46,848,000USD-34,139,000USD49,530,000USD
    Begin Period Cash Flow226,316,000USD289,281,000USD380,259,000USD467,359,000USD94,246,000USD47,398,000USD81,537,000USD31,227,000USD
    End Period Cash Flow183,049,000USD229,132,000USD289,281,000USD380,259,000USD467,359,000USD94,246,000USD47,398,000USD80,757,000USD
    Other Cashflows From Investing Activities2,500,000USD—-5,860,000USD-13,915,000USD183,699,000USD-104,782,000USD-90,053,000USD-434,000USD
    Other Cashflows From Financing Activities15,000,000USD10,865,000USD5,316,000USD10,024,000USD19,503,000USD13,923,000USD4,870,000USD88,822,000USD
    Unclassified Investing Cash Flow25,504,000USD5,076,000USD33,639,000USD—-184,182,000USD104,782,000USD90,074,000USD—
    Unclassified Financing Cash Flow13,556,000USD——269,822,000USD323,861,000USD295,563,000USD-4,870,000USD-88,681,000USD
    Net Borrowings—0USD0USD-1,558,000USD-3,333,000USD-3,333,000USD-2,500,000USD-2,500,000USD
    Issuance Of Capital Stock—0USD-2,000USD269,822,000USD323,861,000USD295,563,000USD156,208,000USD91,181,000USD
    Change To Liabilities———7,383,000USD19,021,000USD-1,711,000USD12,301,000USD3,759,000USD
    Cash And Cash Equivalents Changes———-86,781,000USD373,093,000USD46,827,000USD-34,169,000USD—
    Unclassified Operating Cash Flow——————-1,060,000USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q3 2026Quarterly · 2026-06-30GeographyAmericas77,259,000USDDisclosure
    Q3 2026Quarterly · 2026-06-30GeographyAsia Pacific7,495,000USDDisclosure
    Q3 2026Quarterly · 2026-06-30GeographyEMEA33,622,000USDDisclosure
    Q3 2026Quarterly · 2026-06-30ProductAntibody Discovery56,571,000USDDisclosure
    Q3 2026Quarterly · 2026-06-30ProductNgs Tools61,805,000USDDisclosure
    Q2 2026Quarterly · 2026-03-31GeographyAmericas64,307,000USD0001581280-26-000040
    Q2 2026Quarterly · 2026-03-31GeographyAsia Pacific9,061,000USD0001581280-26-000040
    Q2 2026Quarterly · 2026-03-31GeographyEMEA37,347,000USD0001581280-26-000040
    Q2 2026Quarterly · 2026-03-31ProductAntibody Discovery53,274,000USD0001581280-26-000040
    Q2 2026Quarterly · 2026-03-31ProductNgs Tools57,441,000USD0001581280-26-000040
    Q1 2026Quarterly · 2025-12-31GeographyAmericas58,381,000USD0001581280-26-000019
    Q1 2026Quarterly · 2025-12-31GeographyAsia Pacific6,952,000USD0001581280-26-000019
    Q1 2026Quarterly · 2025-12-31GeographyEMEA38,365,000USD0001581280-26-000019
    Q1 2026Quarterly · 2025-12-31ProductAntibody Discovery51,060,000USD0001581280-26-000019
    Q1 2026Quarterly · 2025-12-31ProductNgs Tools52,638,000USD0001581280-26-000019
    Q4 2025Quarterly · 2025-09-30GeographyAmericas57,295,000USDLegacy provider
    Q4 2025Quarterly · 2025-09-30GeographyAsia Pacific7,162,000USDLegacy provider
    Q4 2025Quarterly · 2025-09-30GeographyEMEA34,552,000USDLegacy provider
    Q4 2025Quarterly · 2025-09-30ProductAntibody Discovery6,443,000USDLegacy provider
    Q4 2025Quarterly · 2025-09-30ProductDna And Biopharma Libraries3,317,000USDLegacy provider
    Q4 2025Quarterly · 2025-09-30ProductNgs Tools53,032,000USDLegacy provider
    Q4 2025Quarterly · 2025-09-30ProductOligo Pools5,002,000USDLegacy provider
    Q4 2025Quarterly · 2025-09-30ProductSynthetic Genes31,215,000USDLegacy provider
    FY 2025Yearly · 2025-09-30GeographyAmericas225,580,000USD0001581280-25-000025
    FY 2025Yearly · 2025-09-30GeographyAsia Pacific26,752,000USD0001581280-25-000025
    FY 2025Yearly · 2025-09-30GeographyEMEA124,240,000USD0001581280-25-000025
    FY 2025Yearly · 2025-09-30ProductAntibody Discovery23,452,000USD0001581280-25-000025
    FY 2025Yearly · 2025-09-30ProductDna And Biopharma Libraries11,184,000USD0001581280-25-000025
    FY 2025Yearly · 2025-09-30ProductNgs Tools208,104,000USD0001581280-25-000025
    FY 2025Yearly · 2025-09-30ProductOligo Pools20,230,000USD0001581280-25-000025
    FY 2025Yearly · 2025-09-30ProductSynthetic Genes113,602,000USD0001581280-25-000025
    Q3 2025Quarterly · 2025-06-30GeographyAmericas59,387,000USD0001581280-25-000009
    Q3 2025Quarterly · 2025-06-30GeographyAsia Pacific5,928,000USD0001581280-25-000009
    Q3 2025Quarterly · 2025-06-30GeographyEMEA30,742,000USD0001581280-25-000009
    Q3 2025Quarterly · 2025-06-30ProductAntibody Discovery5,614,000USD0001581280-25-000009
    Q3 2025Quarterly · 2025-06-30ProductDna And Biopharma Libraries2,056,000USD0001581280-25-000009
    Q3 2025Quarterly · 2025-06-30ProductNgs Tools55,284,000USD0001581280-25-000009
    Q3 2025Quarterly · 2025-06-30ProductOligo Pools5,423,000USD0001581280-25-000009
    Q3 2025Quarterly · 2025-06-30ProductSynthetic Genes27,680,000USD0001581280-25-000009
    Q2 2025Quarterly · 2025-03-31GeographyAmericas55,189,000USD0001581280-26-000040
    Q2 2025Quarterly · 2025-03-31GeographyAsia Pacific6,962,000USD0001581280-26-000040
    Q2 2025Quarterly · 2025-03-31GeographyEMEA30,642,000USD0001581280-26-000040
    Q2 2025Quarterly · 2025-03-31ProductAntibody Discovery5,697,000USD0001628280-25-022154
    Q2 2025Quarterly · 2025-03-31ProductDna And Biopharma Libraries3,017,000USD0001628280-25-022154
    Q2 2025Quarterly · 2025-03-31ProductNgs Tools51,146,000USD0001628280-25-022154
    Q2 2025Quarterly · 2025-03-31ProductOligo Pools4,711,000USD0001628280-25-022154
    Q2 2025Quarterly · 2025-03-31ProductSynthetic Genes28,222,000USD0001628280-25-022154
    Q1 2025Quarterly · 2024-12-31GeographyAmericas53,709,000USD0001581280-26-000019
    Q1 2025Quarterly · 2024-12-31GeographyAsia Pacific6,700,000USD0001581280-26-000019
    Q1 2025Quarterly · 2024-12-31GeographyEMEA28,304,000USD0001581280-26-000019
    Q1 2025Quarterly · 2024-12-31ProductAntibody Discovery5,698,000USD0001628280-25-003461
    Q1 2025Quarterly · 2024-12-31ProductDna And Biopharma Libraries2,794,000USD0001628280-25-003461
    Q1 2025Quarterly · 2024-12-31ProductNgs Tools48,642,000USD0001628280-25-003461
    Q1 2025Quarterly · 2024-12-31ProductOligo Pools5,094,000USD0001628280-25-003461
    Q1 2025Quarterly · 2024-12-31ProductSynthetic Genes26,485,000USD0001628280-25-003461
    Q4 2024Quarterly · 2024-09-30GeographyAmericas52,663,000USDLegacy provider
    Q4 2024Quarterly · 2024-09-30GeographyAsia Pacific6,544,000USDLegacy provider
    Q4 2024Quarterly · 2024-09-30GeographyEMEA25,503,000USDLegacy provider
    Q4 2024Quarterly · 2024-09-30ProductAntibody Discovery5,299,000USDLegacy provider
    Q4 2024Quarterly · 2024-09-30ProductDna And Biopharma Libraries3,615,000USDLegacy provider
    Q4 2024Quarterly · 2024-09-30ProductNgs Tools45,536,000USDLegacy provider
    Q4 2024Quarterly · 2024-09-30ProductOligo Pools4,611,000USDLegacy provider
    Q4 2024Quarterly · 2024-09-30ProductSynthetic Genes25,649,000USDLegacy provider
    FY 2024Yearly · 2024-09-30GeographyAmericas193,884,000USD0001581280-25-000025
    FY 2024Yearly · 2024-09-30GeographyAsia Pacific26,523,000USD0001581280-25-000025
    FY 2024Yearly · 2024-09-30GeographyEMEA92,567,000USD0001581280-25-000025
    FY 2024Yearly · 2024-09-30ProductAntibody Discovery20,328,000USD0001581280-25-000025
    FY 2024Yearly · 2024-09-30ProductDna And Biopharma Libraries13,933,000USD0001581280-25-000025
    FY 2024Yearly · 2024-09-30ProductNgs Tools169,128,000USD0001581280-25-000025
    FY 2024Yearly · 2024-09-30ProductOligo Pools16,906,000USD0001581280-25-000025
    FY 2024Yearly · 2024-09-30ProductSynthetic Genes92,679,000USD0001581280-25-000025
    FY 2023Yearly · 2023-09-30GeographyAmericas151,263,000USD0001581280-25-000025
    FY 2023Yearly · 2023-09-30GeographyAsia Pacific22,457,000USD0001581280-25-000025
    FY 2023Yearly · 2023-09-30GeographyEMEA71,389,000USD0001581280-25-000025
    FY 2023Yearly · 2023-09-30ProductAntibody Discovery23,172,000USD0001581280-25-000025
    FY 2023Yearly · 2023-09-30ProductDna And Biopharma Libraries10,201,000USD0001581280-25-000025
    FY 2023Yearly · 2023-09-30ProductNgs Tools123,706,000USD0001581280-25-000025
    FY 2023Yearly · 2023-09-30ProductOligo Pools14,489,000USD0001581280-25-000025
    FY 2023Yearly · 2023-09-30ProductSynthetic Genes73,541,000USD0001581280-25-000025
    FY 2022Yearly · 2022-09-30GeographyAmericas122,473,000USD0001628280-24-048262
    FY 2022Yearly · 2022-09-30GeographyAsia Pacific19,014,000USD0001628280-24-048262
    FY 2022Yearly · 2022-09-30GeographyEMEA62,078,000USD0001628280-24-048262
    FY 2022Yearly · 2022-09-30ProductAntibody Discovery24,171,000USD0001628280-24-048262
    FY 2022Yearly · 2022-09-30ProductDna And Biopharma Libraries6,149,000USD0001628280-24-048262
    FY 2022Yearly · 2022-09-30ProductNgs Tools99,312,000USD0001628280-24-048262
    FY 2022Yearly · 2022-09-30ProductOligo Pools12,424,000USD0001628280-24-048262
    FY 2022Yearly · 2022-09-30ProductSynthetic Genes61,509,000USD0001628280-24-048262
    FY 2021Yearly · 2021-09-30GeographyAmericas77,909,000USD0001628280-23-039767
    FY 2021Yearly · 2021-09-30GeographyAsia Pacific10,300,000USD0001628280-23-039767
    FY 2021Yearly · 2021-09-30GeographyEMEA44,124,000USD0001628280-23-039767
    FY 2021Yearly · 2021-09-30ProductAntibody Discovery6,985,000USD0001628280-23-039767
    FY 2021Yearly · 2021-09-30ProductDna And Biopharma Libraries5,678,000USD0001628280-23-039767
    FY 2021Yearly · 2021-09-30ProductNgs Tools72,667,000USD0001628280-23-039767
    FY 2021Yearly · 2021-09-30ProductOligo Pools8,039,000USD0001628280-23-039767
    FY 2021Yearly · 2021-09-30ProductSynthetic Genes38,964,000USD0001628280-23-039767
    Q1 2021Quarterly · 2020-12-31SegmentAcademic Research4,901,000USD0001193125-21-032669
    Q1 2021Quarterly · 2020-12-31SegmentFood Or Agriculture152,000USD0001193125-21-032669
    Q1 2021Quarterly · 2020-12-31SegmentHealth Care15,976,000USD0001193125-21-032669
    Q1 2021Quarterly · 2020-12-31SegmentIndustrial Chemicals7,132,000USD0001193125-21-032669
    FY 2020Yearly · 2020-09-30GeographyAmericas1,084,000USD0001193125-20-303904

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.